3.連結財務諸表及び主な注記
(1)連結貸借対照表
|
|
|
|
|
|
|
|
|
|
|
|
(単位:千円)
|
|
|
|
|
|
|
|
|
|
|
|
前連結会計年度
(2024年11月30日)
|
当連結会計年度
(2025年11月30日)
|
|
資産の部
|
|
|
|
|
流動資産
|
|
|
|
|
|
現金及び預金
|
744,643
|
1,212,523
|
|
|
|
受取手形
|
173,530
|
20,578
|
|
|
|
売掛金
|
3,167,938
|
3,044,197
|
|
|
|
電子記録債権
|
23,021
|
230,407
|
|
|
|
製品
|
1,294,816
|
1,051,054
|
|
|
|
仕掛品
|
417,649
|
317,915
|
|
|
|
原材料
|
489,412
|
450,367
|
|
|
|
前払費用
|
17,990
|
18,149
|
|
|
|
その他
|
15,351
|
31,957
|
|
|
|
貸倒引当金
|
△5,719
|
△5,601
|
|
|
|
流動資産合計
|
6,338,634
|
6,371,550
|
|
|
固定資産
|
|
|
|
|
|
有形固定資産
|
|
|
|
|
|
|
建物
|
2,058,345
|
2,120,389
|
|
|
|
|
|
減価償却累計額
|
△1,594,347
|
△1,639,634
|
|
|
|
|
|
建物(純額)
|
463,998
|
480,754
|
|
|
|
|
構築物
|
1,053,749
|
1,067,067
|
|
|
|
|
|
減価償却累計額
|
△736,314
|
△756,243
|
|
|
|
|
|
構築物(純額)
|
317,434
|
310,824
|
|
|
|
|
機械及び装置
|
7,877,433
|
8,476,252
|
|
|
|
|
|
減価償却累計額
|
△6,953,020
|
△7,187,555
|
|
|
|
|
|
機械及び装置(純額)
|
924,412
|
1,288,697
|
|
|
|
|
車両運搬具
|
47,639
|
58,584
|
|
|
|
|
|
減価償却累計額
|
△37,684
|
△42,130
|
|
|
|
|
|
車両運搬具(純額)
|
9,954
|
16,453
|
|
|
|
|
工具、器具及び備品
|
1,171,247
|
1,185,179
|
|
|
|
|
|
減価償却累計額
|
△967,726
|
△1,029,713
|
|
|
|
|
|
工具、器具及び備品(純額)
|
203,521
|
155,465
|
|
|
|
|
土地
|
74,349
|
74,349
|
|
|
|
|
建設仮勘定
|
67,670
|
8,789
|
|
|
|
|
有形固定資産合計
|
2,061,341
|
2,335,333
|
|
|
|
無形固定資産
|
|
|
|
|
|
|
その他
|
13,265
|
9,687
|
|
|
|
|
無形固定資産合計
|
13,265
|
9,687
|
|
|
|
投資その他の資産
|
|
|
|
|
|
|
投資有価証券
|
55,097
|
69,344
|
|
|
|
|
関係会社株式
|
3,000
|
3,000
|
|
|
|
|
長期前払費用
|
100
|
38,058
|
|
|
|
|
退職給付に係る資産
|
―
|
25,554
|
|
|
|
|
繰延税金資産
|
45,321
|
2,521
|
|
|
|
|
その他
|
16,072
|
14,330
|
|
|
|
|
貸倒引当金
|
△1,300
|
△1,300
|
|
|
|
|
投資その他の資産合計
|
118,291
|
151,509
|
|
|
|
固定資産合計
|
2,192,898
|
2,496,531
|
|
|
資産合計
|
8,531,532
|
8,868,081
|
|
|
|
|
|
|
|
|
|
|
|
|
(単位:千円)
|
|
|
|
|
|
|
|
|
|
|
|
前連結会計年度
(2024年11月30日)
|
当連結会計年度
(2025年11月30日)
|
|
負債の部
|
|
|
|
|
流動負債
|
|
|
|
|
|
支払手形
|
42,716
|
15,474
|
|
|
|
買掛金
|
1,360,707
|
1,182,030
|
|
|
|
電子記録債務
|
137,183
|
113,760
|
|
|
|
短期借入金
|
2,160,000
|
2,160,000
|
|
|
|
1年内返済予定の長期借入金
|
452,136
|
99,666
|
|
|
|
未払金
|
362,764
|
339,888
|
|
|
|
未払費用
|
214,624
|
175,692
|
|
|
|
未払法人税等
|
52,867
|
37,973
|
|
|
|
未払消費税等
|
10,182
|
58,006
|
|
|
|
役員賞与引当金
|
17,100
|
18,600
|
|
|
|
設備関係支払手形
|
4,851
|
403
|
|
|
|
設備関係電子記録債務
|
18,850
|
26,587
|
|
|
|
その他
|
53,206
|
48,250
|
|
|
|
流動負債合計
|
4,887,192
|
4,276,334
|
|
|
固定負債
|
|
|
|
|
|
長期借入金
|
452,626
|
1,255,668
|
|
|
|
役員退職慰労引当金
|
86,456
|
101,553
|
|
|
|
退職給付に係る負債
|
109,563
|
―
|
|
|
|
長期預り金
|
90,022
|
90,286
|
|
|
|
リース債務
|
22,074
|
9,526
|
|
|
|
その他
|
1,200
|
1,200
|
|
|
|
固定負債合計
|
761,943
|
1,458,234
|
|
|
負債合計
|
5,649,135
|
5,734,568
|
|
純資産の部
|
|
|
|
|
株主資本
|
|
|
|
|
|
資本金
|
610,000
|
610,000
|
|
|
|
資本剰余金
|
58,437
|
58,437
|
|
|
|
利益剰余金
|
2,156,499
|
2,381,849
|
|
|
|
自己株式
|
△8,326
|
△8,368
|
|
|
|
株主資本合計
|
2,816,610
|
3,041,918
|
|
|
その他の包括利益累計額
|
|
|
|
|
|
その他有価証券評価差額金
|
13,108
|
22,695
|
|
|
|
為替換算調整勘定
|
52,677
|
68,899
|
|
|
|
その他の包括利益累計額合計
|
65,786
|
91,594
|
|
|
純資産合計
|
2,882,396
|
3,133,512
|
|
負債純資産合計
|
8,531,532
|
8,868,081
|
E01006
43610
川口化学工業株式会社
Kawaguchi Chemical Industry Co., Ltd
通期第1号参考様式 [日本基準](連結)
Japan GAAP
true
cte
cte
2024-12-01
2025-11-30
FY
2025-11-30
2023-12-01
2024-11-30
2024-11-30
1
false
false
false
43610
2026-01-14
43610
2024-12-01
2025-11-30
43610
2024-12-01
2025-11-30
jppfs_cor:CapitalStockMember
43610
2024-12-01
2025-11-30
jppfs_cor:CapitalSurplusMember
43610
2024-12-01
2025-11-30
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
43610
2024-12-01
2025-11-30
jpcrp_cor:ReconcilingItemsMember
43610
2024-12-01
2025-11-30
jppfs_cor:RetainedEarningsMember
43610
2024-12-01
2025-11-30
jppfs_cor:ShareholdersEquityMember
43610
2024-12-01
2025-11-30
jpcrp_cor:TotalOfReportableSegmentsAndOthersMember
43610
2024-12-01
2025-11-30
jppfs_cor:TreasuryStockMember
43610
2024-12-01
2025-11-30
tse-acedjpfr-43610:PharmaceuticalProductsReportableSegmentsMember
43610
2024-12-01
2025-11-30
tse-acedjpfr-43610:RealEstateLeasingReportableSegmentMember
43610
2024-12-01
2025-11-30
jppfs_cor:ValuationAndTranslationAdjustmentsMember
43610
2024-12-01
2025-11-30
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
43610
2025-11-30
43610
2025-11-30
jppfs_cor:CapitalStockMember
43610
2025-11-30
jppfs_cor:CapitalSurplusMember
43610
2025-11-30
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
43610
2025-11-30
jpcrp_cor:ReconcilingItemsMember
43610
2025-11-30
jppfs_cor:RetainedEarningsMember
43610
2025-11-30
jppfs_cor:ShareholdersEquityMember
43610
2025-11-30
jpcrp_cor:TotalOfReportableSegmentsAndOthersMember
43610
2025-11-30
jppfs_cor:TreasuryStockMember
43610
2025-11-30
tse-acedjpfr-43610:PharmaceuticalProductsReportableSegmentsMember
43610
2025-11-30
tse-acedjpfr-43610:RealEstateLeasingReportableSegmentMember
43610
2025-11-30
jppfs_cor:ValuationAndTranslationAdjustmentsMember
43610
2025-11-30
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
43610
2023-12-01
2024-11-30
43610
2023-12-01
2024-11-30
jppfs_cor:CapitalStockMember
43610
2023-12-01
2024-11-30
jppfs_cor:CapitalSurplusMember
43610
2023-12-01
2024-11-30
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
43610
2023-12-01
2024-11-30
jpcrp_cor:ReconcilingItemsMember
43610
2023-12-01
2024-11-30
jppfs_cor:RetainedEarningsMember
43610
2023-12-01
2024-11-30
jppfs_cor:ShareholdersEquityMember
43610
2023-12-01
2024-11-30
jpcrp_cor:TotalOfReportableSegmentsAndOthersMember
43610
2023-12-01
2024-11-30
jppfs_cor:TreasuryStockMember
43610
2023-12-01
2024-11-30
tse-acedjpfr-43610:PharmaceuticalProductsReportableSegmentsMember
43610
2023-12-01
2024-11-30
tse-acedjpfr-43610:RealEstateLeasingReportableSegmentMember
43610
2023-12-01
2024-11-30
jppfs_cor:ValuationAndTranslationAdjustmentsMember
43610
2023-12-01
2024-11-30
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
43610
2024-11-30
43610
2024-11-30
jppfs_cor:CapitalStockMember
43610
2024-11-30
jppfs_cor:CapitalSurplusMember
43610
2024-11-30
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
43610
2024-11-30
jpcrp_cor:ReconcilingItemsMember
43610
2024-11-30
jppfs_cor:RetainedEarningsMember
43610
2024-11-30
jppfs_cor:ShareholdersEquityMember
43610
2024-11-30
jpcrp_cor:TotalOfReportableSegmentsAndOthersMember
43610
2024-11-30
jppfs_cor:TreasuryStockMember
43610
2024-11-30
tse-acedjpfr-43610:PharmaceuticalProductsReportableSegmentsMember
43610
2024-11-30
tse-acedjpfr-43610:RealEstateLeasingReportableSegmentMember
43610
2024-11-30
jppfs_cor:ValuationAndTranslationAdjustmentsMember
43610
2024-11-30
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
43610
2023-11-30
43610
2023-11-30
jppfs_cor:CapitalStockMember
43610
2023-11-30
jppfs_cor:CapitalSurplusMember
43610
2023-11-30
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
43610
2023-11-30
jppfs_cor:RetainedEarningsMember
43610
2023-11-30
jppfs_cor:ShareholdersEquityMember
43610
2023-11-30
jppfs_cor:TreasuryStockMember
43610
2023-11-30
jppfs_cor:ValuationAndTranslationAdjustmentsMember
43610
2023-11-30
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
iso4217:JPY
xbrli:pure